ArticleJournal of parasitology research2011
Efficacy of Topical Liposomal Amphotericin B versus Intralesional Meglumine Antimoniate (Glucantime) in the Treatment of Cutaneous Leishmaniasis.
Article in Journal of parasitology research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 4 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Local amphotericin B therapy for Cutaneous Leishmaniasis: A systematic review.PLoS neglected tropical diseases · 2024Pooled it
- Interventions for Old World cutaneous leishmaniasis.The Cochrane database of systematic reviews · 2017Pooled it
- Interventions for Old World cutaneous leishmaniasis.The Cochrane database of systematic reviews · 2017Pooled it
- Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review.PloS one · 2017Pooled it
- Microneedle-based injection of Fungizone/Amphotericin B: an effective treatment for American cutaneous leishmaniasis in mice.Drug delivery · 2026Article
- A 10-year registry-based retrospective study of cutaneous Leishmaniasis in Mashhad, northeastern Iran: Demographic, clinical, and therapeutic profiles of 1537 cases.Parasite epidemiology and control · 2026Article
- Nanofibrous patches for targeted therapy of cutaneous leishmaniasis caused by Leishmania major: a preclinical amphotericin B platform.Parasitology research · 2025Article
- Cutaneous leishmaniasis: epidemiology, treatment access and translational challenges of topical therapies.Frontiers in microbiology · 2025Review
- Biocompatibility and Effectiveness of Amphotericin B-Loaded Metal-Organic Structures (AmB-ZIF-8) as Dermal Drug Transporters in Experimental Cutaneous Leishmaniasis.Journal of experimental pharmacology · 2025Article
- A Case Series of 36 Patients Treated for Old World Cutaneous leishmaniasis.The Journal of clinical and aesthetic dermatology · 2024Article
- Therapeutic advances in the topical treatment of cutaneous leishmaniasis: A review.PLoS neglected tropical diseases · 2021Review
- Antileishmanial activity and immune modulatory effects of benzoxonium chloride and its entrapped forms in niosome onJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2019Article
- Lipsosomal amphotericin B: a review of its properties, function, and use for treatment of cutaneous leishmaniasis.Research and reports in tropical medicine · 2019Article
- Evaluation of the Interventional Approaches in the Management of Cutaneous Leishmaniasis in Jazan: An Observational Study.Annals of dermatology · 2018Article
- Article
- Potential Challenges of Controlling Leishmaniasis in Sri Lanka at a Disease Outbreak.BioMed research international · 2017Review
- An update on pharmacotherapy for leishmaniasis.Expert opinion on pharmacotherapy · 2015Review
- UV Spectrophotometric Determination and Validation of Hydroquinone in Liposome.Iranian journal of pharmaceutical research : IJPR · 2015Article
- Efficacy of intralesional amphotericin B for the treatment of cutaneous leishmaniasis.Indian journal of dermatology · 2014Article
- Immunologic response and memory T cells in subjects cured of tegumentary leishmaniasis.BMC infectious diseases · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background. Topical treatment of cutaneous leishmaniasis is an attractive alternative avoiding toxicities of parenteral therapy while being administered through a simple painless route. Recently liposomal formulations of amphotericin B have been increasingly used in the treatment of several types of leishmaniasis. Aims. The efficacy of a topical liposomal amphotericin B formulation was compared with intralesional glucantime in the treatment of cutaneous leishmaniasis. Methods. From 110 patients, the randomly selected 50 received a topical liposomal formulation of amphotericin B into each lesion, 3-7 drops twice daily, according to the lesion's size and for 8 weeks. The other group of 60 patients received intralesional glucantime injection of 1-2 mL once a week for the same period. The clinical responses and side effects of both groups were evaluated weekly during the treatment course. Results. Per-protocol analysis showed no statistically significant difference between the two groups (P = 0.317, 95% confidence interval (CI) = 1.610 (0.632-4.101)). Moreover, after intention-to-treat analysis, the same results were seen (P = 0.650, 95% CI = 0.1.91 (0.560-2.530)). Serious post treatment side effects were not observed in either group. Conclusions. Topical liposomal amphotericin B has the same efficacy as intralesional glucantime in the treatment of cutaneous leishmaniasis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.